Study/clinical trial | ZO-FAST | ABCSG-12 | GAIN | NSABP-B34 | AZURE | Saarto [32] | Diel [33] | Kristensen [34] | Powles [35] |
---|---|---|---|---|---|---|---|---|---|
N | 1065 | 1803 | 3023 | 3323 | 3360 | 299 | 302 | 953 | 1069 |
Bisphosphonate | Zoledronate i.v. | Zoledronate i.v. | Ibandronate p.o. | Clodronate p.o. | Zoledronate i.v. | Clodronate p.o. | Clodronate p.o. | Pamidronate p.o. | Clodronate p.o. |
Duration of therapy | 5 years | 3 years | 2 years | 3 years | 5 years | 3 years | 2 years | 4 years | 2 years |
Adjuvant therapy | Endocrine (AI) | Endocrine (Tam vs. AI +GnRH-Anal.) | Dose-dense doseintense CTX | CTX +/- Endocrine | CTX +/- Endocrine | CTX +/- Endocrine | CTX +/- Endocrine | CTX | CTX +/- Endocrine |
Follow up | 60 months | 84 months | 39 months | 91 months | 60 months | 120 months | 103 months | n.d. | 66 months |
Premenopausal | - | Yes (DFS, OS) | No | No | No | No | Yes (OS) | No | Yes (OS, bonemetastasis free survival) |
Postmenopausal | Yes (DFS) | - | No (Trend > 60 yrs.) | Yes (> 50 yrs. DFS, but not OS) | Yes (DFS, OS) | Â | Â | Â | Â |